{"id":"NCT01063764","sponsor":"UCB Japan Co. Ltd.","briefTitle":"An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures","officialTitle":"An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2 Anti-Epileptic Drugs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2011-04","completion":"2013-10","firstPosted":"2010-02-05","resultsPosted":"2012-06-19","lastUpdate":"2015-03-05"},"enrollment":73,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Partial Seizures"],"interventions":[{"type":"DRUG","name":"Levetiracetam","otherNames":["Keppra"]}],"arms":[{"label":"Levetiracetam","type":"EXPERIMENTAL"}],"summary":"Objective of the First Period: To evaluate the efficacy of Levetiracetam dry syrup at doses up to a maximum of 60 mg/kg/day or 3000 mg/day used as an adjunctive therapy in Japanese pediatric patients (4 to 16 years) with uncontrolled partial seizures despite treatment with 1 or 2 anti-epileptic drug(s).","primaryOutcome":{"measure":"Change From Baseline in Partial Seizure Frequency Per Week Over the 14-weeks Treatment Period","timeFrame":"From Baseline (Week 0-8) to the 14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22)); Week 0-22","effectByArm":[{"arm":"Levetiracetam","deltaMin":43.21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":29,"countries":["Japan"]},"refs":{"pmids":["24018745"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":73},"commonTop":["Nasopharyngitis","Somnolence","Influenza","Pyrexia","Upper respiratory tract infection"]}}